Rhenman & Partners Asset Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Rhenman & Partners Asset Management’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-8,045	Closed	-$1.01M	–	101
2017 Q4	$1.01M	Buy	+8,045	New	+$1.03M	0.14%	80
2017 Q3	–	Sell	-15,000	Closed	-$2.14M	–	114
2017 Q2	$2.14M	Hold	15,000	–	–	0.31%	78
2017 Q1	$2.76M	Hold	15,000	–	–	0.44%	73
2016 Q4	$1.21M	Hold	15,000	–	–	0.23%	82
2016 Q3	$1.15M	Hold	15,000	–	–	0.18%	87
2016 Q2	$1.29M	Hold	15,000	–	–	0.23%	85
2016 Q1	$1.39M	Buy	15,000 +3,750	+33%	+$375K	0.28%	82
2015 Q4	$2.26M	Hold	11,250	–	–	0.34%	84
2015 Q3	$1.68M	Buy	11,250 +5,880	+109%	+$4.32M	0.27%	84
2015 Q2	$5.09M	Sell	5,370 -730	-12%	-$597K	0.61%	60
2015 Q1	$4.47M	Buy	+6,100	New	+$4.58M	0.75%	47

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Rhenman & Partners Asset Management's TTPH Position: Q1 2018 in Review

Rhenman & Partners Asset Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2018, closing a stake of 8,045 shares — an estimated $1.01M sold.

Rhenman & Partners Asset Management first reported a position in TTPH in Q1 2015 and held it in 11 quarters. The position peaked at $5.09M in Q2 2015. 94 funds tracked by Wall St. Rank hold TTPH as of Q1 2018.

Rhenman & Partners Asset Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Rhenman & Partners Asset Management sold 8,045 Tetraphase Pharmaceuticals, Inc. shares in Q1 2018, an estimated $1.01M.
Rhenman & Partners Asset Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2015 and held it in 11 quarters.
Rhenman & Partners Asset Management's Tetraphase Pharmaceuticals, Inc. position peaked at $5.09M in Q2 2015.
94 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2018.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2018, filed 11 Apr 2018.